SCHEMBL28982178

SCHEMBL28982178

CC(C)(C)OC(=O)NCCCNC(=O)c1ccc(Nc2nccn3c(-c4ccc(OC(F)F)c(F)c4F)cnc23)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK6 Q13882 2/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ ACVR1B P36896 1/20 0.38
▸ TGFBR1 P36897 1/20 0.38
▸ ACVRL1 P37023 1/20 0.38
▸ TTK P33981 2/20 0.35
▸ P2RX3 P56373 4/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ STK17B O94768 1/20 0.34
▸ STK17A Q9UEE5 1/20 0.34
▸ EGFR P00533 3/20 0.34
▸ AURKB Q96GD4 1/20 0.34
▸ PTGES O14684 1/20 0.33
▸ ITK Q08881 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CSNK2A2 P19784 1/20 0.33
▸ CSNK2A1 P68400 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25173405 0.92 BRD4 (0.38) PTK6BRD4ACVR1BTGFBR1ACVRL1
SCHEMBL30385633 0.90 BRD4 (0.38) PTK6BRD4ACVR1BTGFBR1ACVRL1
SCHEMBL28982226 0.89 PTK6 (0.39) PTK6JAK2
Trifluoroacetic Acid SCHEMBL28982169 0.87 PTK6 (0.39) PTK6TTKP2RX3NTRK1EGFR
SCHEMBL22123514 0.87 BRD4 (0.39) PTK6BRD4ACVR1BTGFBR1ACVRL1
SCHEMBL25176130 0.85 PTK6 (0.45) PTK6TTKJAK2AURKB
SCHEMBL30385702 0.85 BRD4 (0.40) PTK6BRD4ACVR1BTGFBR1ACVRL1
SCHEMBL30386008 0.85 BRD4 (0.40) PTK6BRD4ACVR1BTGFBR1ACVRL1
Hydrochloric Acid SCHEMBL25173472 0.85 PTK6 (0.45) PTK6TTKJAK2AURKB
SCHEMBL30384774 0.85 BRD4 (0.40) PTK6BRD4ACVR1BTGFBR1ACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 — — EP disclosed
US-20230141600-A1 IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
EP-4161931-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-04-12 — — EP disclosed
CN-115916784-A Novel imidazopyrazine derivatives 豪夫迈·罗氏有限公司 2023-04-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141600-A1 IMIDAZOPYRAZINE DERIVATIVES IKZF3, RRP15, IK PTK6 925/4885BRD4 483/4885ACVR1B 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback